The subtype characterized by the overexpression of estrogen receptors (ER+ breast cancer) accounts for approximately 70% of all breast cancer cases and has seen significant treatment advancements due to the introduction of combined therapy of endocrine and CDK4/6 inhibitor (Blakely et al., 2023). Here, CDK4 is linked to breast carcinoma.